D
David Donley
Researcher at Quintiles
Publications - 3
Citations - 744
David Donley is an academic researcher from Quintiles. The author has contributed to research in topics: NPH insulin & Insulin glargine. The author has an hindex of 3, co-authored 3 publications receiving 732 citations.
Papers
More filters
Journal ArticleDOI
Basal Insulin Therapy in Type 2 Diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin
TL;DR: In patients with type 2 diabetes, once-daily bedtime insulin glargine is as effective as once- or twice-daily NPH in improving and maintaining glycemic control and deonstrates a lower risk of nocturnal hypoglycemia and less weight gain compared with NPH insulin.
Journal ArticleDOI
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
Philip Raskin,Leslie Klaff,Richard M. Bergenstal,Jean Pierre Hallé,David Donley,Thomas E. Mecca +5 more
TL;DR: Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro.